Literature DB >> 15581976

Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors.

Syed Hamid Ali1, Amy L O'Donnell, Seema Mohamed, Shaker Mousa, Paresh Dandona.   

Abstract

BACKGROUND: A high level of estrogen receptor-alpha (ER-alpha) is believed to be favorable in the prognosis and treatment of endometrial, ovarian, and breast cancer. High levels of ER-alpha have been shown to inhibit the growth and invasive, metastatic potential of breast cancer cell lines. To bring about these inhibitory effects, ER-alpha probably acts through other cellular factors involved in the regulation of cell growth.
OBJECTIVE: To investigate the role of high levels ER-alpha in growth inhibition of endometrial cancer cells.
METHODS: A human ER-alpha cDNA was stably overexpressed in an endometrial cancer cell line, namely, Ishikawa. ER-alpha-overexpressing, parent, and control Ishikawa cells were grown in vitro and their growth rates were compared by cell count. ER-alpha-overexpressing and parent Ishikawa cells were also grown in vitro as tumors in a chicken chorioallantoic membrane (CAM) model, and tumor growth and angiogenesis was measured. Finally, levels of angiogenesis-modulating factors, nitric oxide synthase (NOS), and vascular endothelial growth factor (VEGF) were examined in relation to ER overexpression.
RESULTS: The growth of Ishikawa cells was found inhibited in culture as well as in the CAM model. Angiogenesis of CAM tumors was also found inhibited in ER-overexpressing cells. Angiogenic factor VEGF was inhibited whereas the activity of NOS was found elevated following ER overexpression.
CONCLUSION: Our work on the Ishikawa cell line indicates that high levels of ER-alpha in endometrial cancer may inhibit cancer growth by modulating angiogenic factors, thereby limiting the blood supply to the growing tumor. Our results support the earlier data from other groups that have shown a positive correlation between high ER content and better prognosis of endometrial cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15581976     DOI: 10.1016/j.ygyno.2004.08.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer.

Authors:  Matthew Saldana; Kacey VanderVorst; Anastasia L Berg; Hyun Lee; Kermit L Carraway
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

2.  Estrogen-induced maldevelopment of the penis involves down-regulation of myosin heavy chain 11 (MYH11) expression, a biomarker for smooth muscle cell differentiation.

Authors:  L A Okumu; Sequoia Bruinton; Tim D Braden; Liz Simon; Hari O Goyal
Journal:  Biol Reprod       Date:  2012-11-08       Impact factor: 4.285

3.  Loss of estrogen receptor 1 enhances cervical cancer invasion.

Authors:  Yali Zhai; Guido T Bommer; Ying Feng; Alexandra B Wiese; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

4.  Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.

Authors:  Shunjun Zhao; Genxia Li; Li Yang; Lei Li; Hongyu Li
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

5.  Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure.

Authors:  Gonda Fj Konings; Niina Saarinen; Bert Delvoux; Loes Kooreman; Pasi Koskimies; Camilla Krakstad; Kristine E Fasmer; Ingfrid S Haldorsen; Amina Zaffagnini; Merja R Häkkinen; Seppo Auriola; Ludwig Dubois; Natasja Lieuwes; Frank Verhaegen; Lotte Ejr Schyns; Roy Fpm Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Int J Mol Sci       Date:  2018-08-28       Impact factor: 5.923

Review 6.  Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers.

Authors:  Lawrence Kasherman; Shiru Lucy Liu; Katherine Karakasis; Stephanie Lheureux
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

7.  Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.

Authors:  Jinzhi Lai; Tianwen Xu; Hainan Yang
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.